Seismic is a leading sales and marketing enablement platform that enhances the effectiveness of sales teams by providing them with the right content, information, and tools at the right time. The platform leverages artificial intelligence and machine learning to personalize buyer experiences and automate manual sales processes.

We are The Machine Learning Immunology Company. Seismic Therapeutic is a biotechnology company integrating machine learning across the entire biologics drug discovery and development process. Using our IMPACT™ platform, we are  fully integrating machine learning with the key elements of biologics drug discovery – structural biology, protein engineering and translational immunology – to create optimized therapies for patients. Seismic Therapeutic has an emerging pipeline of novel approaches to address adaptive immune system dysregulation to treat autoimmune diseases. The company is backed by a strong syndicate of life sciences investors and is located in the Boston biotechnology hub.

Samsara BioCapital

Polaris Partners

Lightspeed Venture Partners

Boxer Capital

Google Ventures

Timothy A. Springer

Alexandria Venture Investments

Gaingels

GC&H Investments

Bessemer Venture Partners

Codon Capital

Amgen Ventures

Seismic Therapeutic

What does it mean to be a Seismonaut? We inspire each other to make an impact on the world not only through our work, but also by nurturing our diverse communities and the next generation of life science leaders. #WeAreSeismic 

Members of Seismic’s Development team had a great weekend at #AAAAI24 in Washington DC -- the American Academy of Allergy Asthma and Immunology (AAAAI) Annual Meeting, or “quad-AI.” They gained valuable understanding of the opportunities for our pan-IgG protease program. #SeismonautsInAction

We’re pleased to congratulate our Seismonaut colleagues who were recently promoted or received expanded titles based on their outstanding work. Thank you for your great contributions, and we are excited for your accomplishments in your new roles. #SeismonautsInAction 

Congratulations to John Sundy, MD, PhD, our CMO and Head of R&D, for his nomination as an Independent Director to the Board of Directors of Sanofi! #SeismonautsInAction 

Congratulations to Seismic ML team member Nathan Rollins and scientific co-founder Debora Marks on the publication of their review article titled “Machine learning for functional protein design” in the journal Nature Biotechnology. #SeismonautsInAction 

COM:SEISMICTX

Seismic

Analysis Not Available